Update on Lundbeck's total number of voting rights and total share capital

H. Lundbeck A/S (Lundbeck) today publishes the total number of voting rights and
total share capital in the company cf. section 6 of the Executive Order on
Issuers' Disclosure Obligations:

  * Total Number of Voting Rights: 196,135,918 (previously: 196,116,634)
  * Total Share Capital: DKK 980,679,590 (previously: DKK 980,583,170

As communicated on 16 May 2011 (release no 438) and also in connection with the
company's results for the first nine months of 2010 (3 November 2010), Lundbeck
operates with Long-Term Incentive schemes (LTI) for the executive management and
key employees in Denmark and abroad. To fund the programme Lundbeck has bought
the necessary Lundbeck shares in full compliance with the existing NASDAQ OMX
Copenhagen rules regarding trading with treasury shares and Lundbeck's internal
rules.


The number of treasury shares included in the schemes currently amounts to less
than 0.1% of the share capital per scheme. The purchases to fund the programme
will be made as late as possible in order to mirror the final number needed. For
the 2012 and 2013 transfer of shares, the corresponding figures are 89,740 and
94,953 shares, which is equal to approximately DKK 12 million and DKK 13 million
at the present share price.


The schemes are charged continuously to the P&L and the purchase of treasury
shares will have no effect on the P&L.

Financial guidance
The content of this release will have no influence on the Lundbeck Group's
financial guidance for 2011 which was provided on 24 February 2011 in connection
with the release of the financial results for 2010.

Lundbeck contacts

Investors:                           Media:



Palle Holm Olesen                    Mads Kronborg

Chief Specialist, Investor Relations Media Relations Manager

+45 36 43 24 26                      +45 36 43 28 51



Magnus Thorstholm Jensen             Simon Mehl Augustesen

Investor Relations Officer           International Media Specialist

+45 36 43 38 16                      +45 36 43 49 80



Jacob Tolstrup

Vice President

+1 847 282 5713


About Lundbeck
H. Lundbeck A/S (LUN.CO, LUN DC, HLUKY) is an international pharmaceutical
company highly committed to improving the quality of life for people suffering
from central nervous system (CNS) disorders. For this purpose, Lundbeck is
engaged in the research, development, production, marketing and sale of
pharmaceuticals across the world. The company's products are targeted at
disorders such as depression and anxiety, schizophrenia, insomnia, epilepsy and
Huntington's, Alzheimer's and Parkinson's diseases.

Lundbeck was founded in 1915 by Hans Lundbeck in Copenhagen, Denmark. Today
Lundbeck employs approximately 5,900 people worldwide. Lundbeck is one of the
world's leading pharmaceutical companies working with CNS disorders. In 2010,
the company's revenue was DKK 14.8 billion (approximately EUR 2.0 billion or USD
2.6 billion). For more information, please visit www.lundbeck.com.


[HUG#1520232]